SEC filings and other documents

Late-stage assets in oncology, neuroscience, and cardiovascular are approaching major readouts.

Growth portfolio and pipeline advances set the stage for sustained sector leadership.

Strong growth portfolio and strategic initiatives drive optimism despite patent and performance risks.

Growth portfolio up 9% and revenue reached $11.5B, with pipeline and guidance momentum.

Late-stage pipeline readouts and robust product growth position the company for sustained expansion.

Six pivotal readouts in 2026 and over 10 new medicines by 2030 drive long-term growth.

Growth portfolio drives double-digit gains; 2026 revenue guided at $46–$47.5B, EPS $6.05–$6.35.

CELMoDs and CAR-T therapies show strong efficacy, driving a promising hematology pipeline.

Cobenfy and Camzyos drive growth as AI, new indications, and direct-to-patient models expand impact.

Growth portfolio sales up 17% year-over-year, driving raised revenue guidance and robust pipeline progress.

CAR T innovation and access expansion are driving growth and new opportunities in cell therapy.

Strong Q2 growth, pipeline progress, and Cobenfy launch position the company for long-term success.

Q2 2025 saw strong growth, raised guidance, and major partnerships fueling future momentum.

BioNTech partnership, strong launches, and a rich pipeline drive growth and future innovation.

Focused on growth, pipeline execution, and financial discipline amid industry headwinds.

Strong financial growth, pipeline advances, all management proposals approved; DEI, sustainability proposals rejected.

Growth portfolio drives raised 2025 guidance despite overall sales decline.